Hypopituitarism — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for hypopituitarism. 36 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
36
Active US patents
72/100
Avg vulnerability
—
Annual revenue covered

Originators in Hypopituitarism

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Besins Hlthcare 36 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating hypopituitarism. Each bar = one year. Y-axis scaled to peak year (24 patents).

24
26
4
27
8
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Androgel
TESTOSTERONE
 Besins Hlthcare 36 72 — 2026-10-12

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8466137 Androgel method of use 85 2026-10-12
8741881 Androgel method of use 85 2026-10-12
8741881 Androgel method of use 85 2026-10-12
8466138 Androgel method of use 85 2026-10-12
8466138 Androgel method of use 85 2026-10-12
8466137 Androgel method of use 85 2026-10-12
8466137 Androgel method of use 85 2026-10-12
8466138 Androgel method of use 85 2026-10-12
8741881 Androgel method of use 85 2026-10-12
8419307 Androgel method of use 85 2027-02-26

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11090312 Androgel method of use 62 2034-03-17
9295675 Androgel method of use 62 2034-02-11
9662340 Androgel method of use 62 2034-02-11
9295675 Androgel method of use 62 2034-02-11
9662340 Androgel method of use 62 2034-02-11
8754070 Androgel formulation 65 2026-10-12
8754070 Androgel formulation 65 2026-10-12
8759329 Androgel formulation 65 2026-10-12
8759329 Androgel formulation 65 2026-10-12
8486925 Androgel formulation 65 2026-10-12

Related